PMP22 and diabetes mellitus: Significantly, targeted activation of the liver X receptor signaling pathway or specific inhibition of the ROS-producing enzyme NADPH oxidase-4 in vivo and in vitro reduces diabetes-induced ROS production in SCs, thereby reversing the functional alterations of peripheral nerves and restoring the homeostatic profiles of MPZ and peripheral myelin protein 22 (PMP22) [299].